Moonoa

High-Level Overview

Moonoa is a Barcelona-based health tech company developing a digital therapeutics platform to combat sleep disorders like insomnia, narcolepsy, and parasomnia using cognitive behavioral therapy (CBT-i).[1][4] It serves individuals struggling with sleep issues by offering a personalized app with over 1,000 content pieces, monthly food supplements tailored to user profiles, and clinically validated programs that have shown 90% of patients reporting better sleep and over 80% reducing reliance on sleeping pills.[1][4] The company raised €1.54 million in a 2021 seed round led by Seedrocket 4founders, with participation from K Fund, Cabiedes, and notable angels, positioning it for growth in the booming digital health space amid rising insomnia post-Covid.[1]

Moonoa's solution is certified as a medical device by the Spanish Medicines Agency and the EU, emphasizing telemedicine's benefits like accessibility, cost reduction, and shorter wait times over traditional care.[1]

Origin Story

Founded in October 2020 by serial entrepreneurs Pablo Szefner (CEO), Caroline Jacquet, Fanny Dubrule, and David Rodriguez Ureña, Moonoa emerged as a direct response to the surge in insomnia exacerbated by Covid-19.[1] The team's entrepreneurial backgrounds drove the creation of a CBT-i-based platform, backed by over 100 clinical studies demonstrating strong efficacy.[1] Early traction included securing medical device certification and launching with app-based content and supplements, culminating in the €1.54 million seed raise in May 2021 to scale operations and reach more users.[1]

Core Differentiators

• Clinically Proven CBT-i Delivery: Unlike generic sleep apps, Moonoa uses evidence-based cognitive behavioral therapy for insomnia, with 90% efficacy in improving sleep and 80%+ reduction in pill dependency from 100+ studies; EU and Spanish certified as a medical device.[1][4]
• Personalized Multimodal Approach: Combines an app with 1,000+ tailored content pieces, monthly profile-based food supplements, and programs for insomnia, narcolepsy, and parasomnia, making it accessible via telemedicine.[1][4]
• Affordable and Enjoyable Accessibility: Focuses on durable habit change for sleep and mental health through enjoyable, low-cost products, reducing barriers compared to in-person therapy.[3][5]
• Holistic Health Focus: Targets root causes in the health and wellness sector, empowering users with sustainable solutions over symptomatic fixes.[2]

Role in the Broader Tech Landscape

Moonoa rides the digital therapeutics wave, capitalizing on post-pandemic insomnia spikes and the shift to telemedicine for mental health.[1] Timing aligns with growing demand for non-pharmacological sleep solutions, as Covid accelerated sleep disorders while enabling app-based delivery that cuts costs and wait times.[1] Favorable market forces include EU regulatory support for medical devices and investor interest in health tech, as seen in its seed funding from prominent European VCs.[1] It influences the ecosystem by validating CBT-i scalability, potentially inspiring more startups in personalized wellness tech amid a global sleep crisis affecting productivity and mental health.

Quick Take & Future Outlook

Moonoa is poised for expansion with its validated model, likely pursuing Series A funding to grow user base and internationalize beyond Europe, leveraging telemedicine trends.[1] Rising AI integration in health apps and sustained focus on mental wellness post-Covid will shape its path, with potential partnerships in wearables or pharma for broader adoption. Its influence could evolve from niche sleep aid to a leader in digital CBT, empowering millions to ditch pills for lasting habits—transforming how we tackle the modern insomnia epidemic that sparked its founding.[1][4]